Biodesix Inc (BDSX) stock
BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$8.40−0.48 (-5.41%)
Close on Nov 18, 2026Market cap $88.63MP/E –Yield –
Biodesix free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Biodesix's free cash flow for the twelve months ending Jun 30, 2026 was -$20.24M. For fiscal 2025 it was -$23.53M. The highest annual figure on record is -$23.04M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$23.53M | – |
| FY2024 | Dec 31, 2024 | -$51.88M | – |
| FY2023 | Dec 31, 2023 | -$45.79M | – |
| FY2022 | Dec 31, 2022 | -$48.27M | – |
| FY2021 | Dec 31, 2021 | -$30.46M | – |
| FY2020 | Dec 31, 2020 | -$23.31M | – |
| FY2019 | Dec 31, 2019 | -$23.04M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.76M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.25M | – |
| Q4 FY2025 | Dec 31, 2025 | $692.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.93M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.62M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.90M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.55M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.68M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.48M | – |
| Q1 FY2023 | Mar 31, 2023 | -$15.36M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.88M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.11M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.92M | -1326.6% |
| Q1 FY2022 | Mar 31, 2022 | -$13.36M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.73M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.75M | – |
| Q2 FY2021 | Jun 30, 2021 | $809.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.22M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.44M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.64M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.12M | – |
See a number that looks wrong?